Skip to content

A prospective cohort study of the efficacy of GnRH-ant pretreatment on antagonist regimens for in vitro fertilization embryo transfer in patients with PCOS

A prospective cohort study of the efficacy of GnRH-ant pretreatment on antagonist regimens for in vitro fertilization embryo transfer in patients with PCOS

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400083905
Enrollment
Unknown
Registered
2024-05-07
Start date
2024-05-10
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome

Interventions

experimental group:With GnRH-ant preprocessing
control group:Without GnRH-ant preprocessing

Sponsors

The People's Hospital of Guangxi Zhuang Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1: PCOS was diagnosed according to the 2003 Rotterdam criteria 2: the age of the woman was <35 years old 3: No hormone drugs were taken within 3 months before inclusion, bilateral ovaries were present, and vaginal B-ultrasound ovaries showed 4: Normal endometrium, no history of uterine surgery

Exclusion criteria

Exclusion criteria: 1: With other diseases that can cause hyperandrogen or abnormal ovulation (e.g., thyroid diseases, Hyperprolactitinemia, adrenal tumor, etc.) 2: History of uterine and ovarian surgery 3: Decreased ovarian reserve function FSH>12U/L or AFC<8 or AMH<1.1ng/ml 4: Endometrial lesions (endometrial breath Meat, uterine adhesion history, etc.), uterine malformation, uterine fibroids (fibroids larger than 3cm or related to the endometrium Close), endometriosis III-IV, adenomyosis, tubal effusion, etc 5: Relapse History of sexual abortion, repeated implantation failure, chromosomal abnormalities 6: serious asthenospermia or obstruction Sexual azoospermia

Design outcomes

Primary

MeasureTime frame
the rate of high-quality embryo;

Secondary

MeasureTime frame
retrieved oocytes; the metaphase II (MII) oocyte rate; the clinical pregnancy rate;the live birth rate;the cumulative pregnancy rate;the cumulative live birth rate;

Countries

China

Contacts

Public ContactLiling Liu

The People's Hospital of Guangxi Zhuang Autonomous Region

liulilingnn@126.com+86 138 7711 1226

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026